転移性メラノーマ治療薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Metastatic Melanoma Drug Market Insights and Forecast to 2028

• レポートコード：QY2203B12437
• 出版社/出版日：QYResearch / 2022年3月
• レポート形態：英文、PDF、107ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥686,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,029,000 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,372,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症のパンデミックにより、世界の転移性メラノーマ治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に転移性メラノーマ治療薬の世界市場のxxx％を占める「AGI-134」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
中国の転移性メラノーマ治療薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの転移性メラノーマ治療薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの転移性メラノーマ治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

転移性メラノーマ治療薬のグローバル主要メーカーには、Merck & Co., Inc.、Merck KGaA、Millennium Pharmaceuticals, Inc.、Morphotek, Inc.、NewLink Genetics Corporation、Novartis AG、Omeros Corporation、Oncolytics Biotech Inc.、OncoSec Medical Inc.、Ono Pharmaceutical Co., Ltd.、Pfizer Inc.、Pharmis Biofarmaceutica, Lda.、Philogen S.p.A.、Plexxikon Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

転移性メラノーマ治療薬市場は、種類と用途によって区分されます。世界の転移性メラノーマ治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
AGI-134、ALT-801、ALT-803、AMG-232、その他

【用途別セグメント】
病院、診療所、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 転移性メラノーマ治療薬製品概要
- 種類別市場（AGI-134、ALT-801、ALT-803、AMG-232、その他）
- 用途別市場（病院、診療所、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の転移性メラノーマ治療薬販売量予測2017-2028
- 世界の転移性メラノーマ治療薬売上予測2017-2028
- 転移性メラノーマ治療薬の地域別販売量
- 転移性メラノーマ治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別転移性メラノーマ治療薬販売量
- 主要メーカー別転移性メラノーマ治療薬売上
- 主要メーカー別転移性メラノーマ治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（AGI-134、ALT-801、ALT-803、AMG-232、その他）
- 転移性メラノーマ治療薬の種類別販売量
- 転移性メラノーマ治療薬の種類別売上
- 転移性メラノーマ治療薬の種類別価格
・用途別市場規模（病院、診療所、その他）
- 転移性メラノーマ治療薬の用途別販売量
- 転移性メラノーマ治療薬の用途別売上
- 転移性メラノーマ治療薬の用途別価格
・北米市場
- 北米の転移性メラノーマ治療薬市場規模（種類別、用途別）
- 主要国別の転移性メラノーマ治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの転移性メラノーマ治療薬市場規模（種類別、用途別）
- 主要国別の転移性メラノーマ治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の転移性メラノーマ治療薬市場規模（種類別、用途別）
- 主要国別の転移性メラノーマ治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の転移性メラノーマ治療薬市場規模（種類別、用途別）
- 主要国別の転移性メラノーマ治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの転移性メラノーマ治療薬市場規模（種類別、用途別）
- 主要国別の転移性メラノーマ治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Merck & Co., Inc.、Merck KGaA、Millennium Pharmaceuticals, Inc.、Morphotek, Inc.、NewLink Genetics Corporation、Novartis AG、Omeros Corporation、Oncolytics Biotech Inc.、OncoSec Medical Inc.、Ono Pharmaceutical Co., Ltd.、Pfizer Inc.、Pharmis Biofarmaceutica, Lda.、Philogen S.p.A.、Plexxikon Inc.
・産業チェーン及び販売チャネル分析
- 転移性メラノーマ治療薬の産業チェーン分析
- 転移性メラノーマ治療薬の原材料
- 転移性メラノーマ治療薬の生産プロセス
- 転移性メラノーマ治療薬の販売及びマーケティング
- 転移性メラノーマ治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 転移性メラノーマ治療薬の産業動向
- 転移性メラノーマ治療薬のマーケットドライバー
- 転移性メラノーマ治療薬の課題
- 転移性メラノーマ治療薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Metastatic Melanoma Drug Market
Due to the COVID-19 pandemic, the global Metastatic Melanoma Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, AGI-134 accounting for % of the Metastatic Melanoma Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Metastatic Melanoma Drug market size is valued at US$ million in 2021, while the US and Europe Metastatic Melanoma Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Metastatic Melanoma Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Metastatic Melanoma Drug include Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc. and OncoSec Medical Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Metastatic Melanoma Drug Scope and Segment
Metastatic Melanoma Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Metastatic Melanoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
AGI-134
ALT-801
ALT-803
AMG-232
Others
Segment by Application
Hospital
Clinic
Others
By Company
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
Plexxikon Inc.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

レポート目次

1 Study Coverage
1.1 Metastatic Melanoma Drug Product Introduction
1.2 Market by Type
1.2.1 Global Metastatic Melanoma Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 AGI-134
1.2.3 ALT-801
1.2.4 ALT-803
1.2.5 AMG-232
1.2.6 Others
1.3 Market by Application
1.3.1 Global Metastatic Melanoma Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Metastatic Melanoma Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Metastatic Melanoma Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Metastatic Melanoma Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Metastatic Melanoma Drug Sales by Region
2.4.1 Global Metastatic Melanoma Drug Sales by Region (2017-2022)
2.4.2 Global Sales Metastatic Melanoma Drug by Region (2023-2028)
2.5 Global Metastatic Melanoma Drug Revenue by Region
2.5.1 Global Metastatic Melanoma Drug Revenue by Region (2017-2022)
2.5.2 Global Metastatic Melanoma Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Metastatic Melanoma Drug Sales by Manufacturers
3.1.1 Global Top Metastatic Melanoma Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Metastatic Melanoma Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Metastatic Melanoma Drug in 2021
3.2 Global Metastatic Melanoma Drug Revenue by Manufacturers
3.2.1 Global Metastatic Melanoma Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Metastatic Melanoma Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Metastatic Melanoma Drug Revenue in 2021
3.3 Global Metastatic Melanoma Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Metastatic Melanoma Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Metastatic Melanoma Drug Sales by Type
4.1.1 Global Metastatic Melanoma Drug Historical Sales by Type (2017-2022)
4.1.2 Global Metastatic Melanoma Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
4.2 Global Metastatic Melanoma Drug Revenue by Type
4.2.1 Global Metastatic Melanoma Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Metastatic Melanoma Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
4.3 Global Metastatic Melanoma Drug Price by Type
4.3.1 Global Metastatic Melanoma Drug Price by Type (2017-2022)
4.3.2 Global Metastatic Melanoma Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Metastatic Melanoma Drug Sales by Application
5.1.1 Global Metastatic Melanoma Drug Historical Sales by Application (2017-2022)
5.1.2 Global Metastatic Melanoma Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
5.2 Global Metastatic Melanoma Drug Revenue by Application
5.2.1 Global Metastatic Melanoma Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Metastatic Melanoma Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
5.3 Global Metastatic Melanoma Drug Price by Application
5.3.1 Global Metastatic Melanoma Drug Price by Application (2017-2022)
5.3.2 Global Metastatic Melanoma Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Metastatic Melanoma Drug Market Size by Type
6.1.1 North America Metastatic Melanoma Drug Sales by Type (2017-2028)
6.1.2 North America Metastatic Melanoma Drug Revenue by Type (2017-2028)
6.2 North America Metastatic Melanoma Drug Market Size by Application
6.2.1 North America Metastatic Melanoma Drug Sales by Application (2017-2028)
6.2.2 North America Metastatic Melanoma Drug Revenue by Application (2017-2028)
6.3 North America Metastatic Melanoma Drug Market Size by Country
6.3.1 North America Metastatic Melanoma Drug Sales by Country (2017-2028)
6.3.2 North America Metastatic Melanoma Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Metastatic Melanoma Drug Market Size by Type
7.1.1 Europe Metastatic Melanoma Drug Sales by Type (2017-2028)
7.1.2 Europe Metastatic Melanoma Drug Revenue by Type (2017-2028)
7.2 Europe Metastatic Melanoma Drug Market Size by Application
7.2.1 Europe Metastatic Melanoma Drug Sales by Application (2017-2028)
7.2.2 Europe Metastatic Melanoma Drug Revenue by Application (2017-2028)
7.3 Europe Metastatic Melanoma Drug Market Size by Country
7.3.1 Europe Metastatic Melanoma Drug Sales by Country (2017-2028)
7.3.2 Europe Metastatic Melanoma Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Metastatic Melanoma Drug Market Size by Type
8.1.1 Asia Pacific Metastatic Melanoma Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Metastatic Melanoma Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Metastatic Melanoma Drug Market Size by Application
8.2.1 Asia Pacific Metastatic Melanoma Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Metastatic Melanoma Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Metastatic Melanoma Drug Market Size by Region
8.3.1 Asia Pacific Metastatic Melanoma Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Metastatic Melanoma Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Metastatic Melanoma Drug Market Size by Type
9.1.1 Latin America Metastatic Melanoma Drug Sales by Type (2017-2028)
9.1.2 Latin America Metastatic Melanoma Drug Revenue by Type (2017-2028)
9.2 Latin America Metastatic Melanoma Drug Market Size by Application
9.2.1 Latin America Metastatic Melanoma Drug Sales by Application (2017-2028)
9.2.2 Latin America Metastatic Melanoma Drug Revenue by Application (2017-2028)
9.3 Latin America Metastatic Melanoma Drug Market Size by Country
9.3.1 Latin America Metastatic Melanoma Drug Sales by Country (2017-2028)
9.3.2 Latin America Metastatic Melanoma Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Metastatic Melanoma Drug Market Size by Type
10.1.1 Middle East and Africa Metastatic Melanoma Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Metastatic Melanoma Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Metastatic Melanoma Drug Market Size by Application
10.2.1 Middle East and Africa Metastatic Melanoma Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Metastatic Melanoma Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Metastatic Melanoma Drug Market Size by Country
10.3.1 Middle East and Africa Metastatic Melanoma Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Merck & Co., Inc.
11.1.1 Merck & Co., Inc. Corporation Information
11.1.2 Merck & Co., Inc. Overview
11.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck & Co., Inc. Recent Developments
11.2 Merck KGaA
11.2.1 Merck KGaA Corporation Information
11.2.2 Merck KGaA Overview
11.2.3 Merck KGaA Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck KGaA Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck KGaA Recent Developments
11.3 Millennium Pharmaceuticals, Inc.
11.3.1 Millennium Pharmaceuticals, Inc. Corporation Information
11.3.2 Millennium Pharmaceuticals, Inc. Overview
11.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Millennium Pharmaceuticals, Inc. Recent Developments
11.4 Morphotek, Inc.
11.4.1 Morphotek, Inc. Corporation Information
11.4.2 Morphotek, Inc. Overview
11.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Morphotek, Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Morphotek, Inc. Recent Developments
11.5 NewLink Genetics Corporation
11.5.1 NewLink Genetics Corporation Corporation Information
11.5.2 NewLink Genetics Corporation Overview
11.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 NewLink Genetics Corporation Recent Developments
11.6 Novartis AG
11.6.1 Novartis AG Corporation Information
11.6.2 Novartis AG Overview
11.6.3 Novartis AG Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Novartis AG Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Novartis AG Recent Developments
11.7 Omeros Corporation
11.7.1 Omeros Corporation Corporation Information
11.7.2 Omeros Corporation Overview
11.7.3 Omeros Corporation Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Omeros Corporation Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Omeros Corporation Recent Developments
11.8 Oncolytics Biotech Inc.
11.8.1 Oncolytics Biotech Inc. Corporation Information
11.8.2 Oncolytics Biotech Inc. Overview
11.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Oncolytics Biotech Inc. Recent Developments
11.9 OncoSec Medical Inc.
11.9.1 OncoSec Medical Inc. Corporation Information
11.9.2 OncoSec Medical Inc. Overview
11.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 OncoSec Medical Inc. Recent Developments
11.10 Ono Pharmaceutical Co., Ltd.
11.10.1 Ono Pharmaceutical Co., Ltd. Corporation Information
11.10.2 Ono Pharmaceutical Co., Ltd. Overview
11.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Ono Pharmaceutical Co., Ltd. Recent Developments
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Corporation Information
11.11.2 Pfizer Inc. Overview
11.11.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Pfizer Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Pfizer Inc. Recent Developments
11.12 Pharmis Biofarmaceutica, Lda.
11.12.1 Pharmis Biofarmaceutica, Lda. Corporation Information
11.12.2 Pharmis Biofarmaceutica, Lda. Overview
11.12.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Pharmis Biofarmaceutica, Lda. Recent Developments
11.13 Philogen S.p.A.
11.13.1 Philogen S.p.A. Corporation Information
11.13.2 Philogen S.p.A. Overview
11.13.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Philogen S.p.A. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Philogen S.p.A. Recent Developments
11.14 Plexxikon Inc.
11.14.1 Plexxikon Inc. Corporation Information
11.14.2 Plexxikon Inc. Overview
11.14.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Plexxikon Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Plexxikon Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Metastatic Melanoma Drug Industry Chain Analysis
12.2 Metastatic Melanoma Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Metastatic Melanoma Drug Production Mode & Process
12.4 Metastatic Melanoma Drug Sales and Marketing
12.4.1 Metastatic Melanoma Drug Sales Channels
12.4.2 Metastatic Melanoma Drug Distributors
12.5 Metastatic Melanoma Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Metastatic Melanoma Drug Industry Trends
13.2 Metastatic Melanoma Drug Market Drivers
13.3 Metastatic Melanoma Drug Market Challenges
13.4 Metastatic Melanoma Drug Market Restraints
14 Key Findings in The Global Metastatic Melanoma Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Metastatic Melanoma Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of AGI-134
Table 3. Major Manufacturers of ALT-801
Table 4. Major Manufacturers of ALT-803
Table 5. Major Manufacturers of AMG-232
Table 6. Major Manufacturers of Others
Table 7. Global Metastatic Melanoma Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Metastatic Melanoma Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Metastatic Melanoma Drug Sales by Region (2017-2022) & (K Pcs)
Table 10. Global Metastatic Melanoma Drug Sales Market Share by Region (2017-2022)
Table 11. Global Metastatic Melanoma Drug Sales by Region (2023-2028) & (K Pcs)
Table 12. Global Metastatic Melanoma Drug Sales Market Share by Region (2023-2028)
Table 13. Global Metastatic Melanoma Drug Revenue by Region (2017-2022) & (US$ Million)
Table 14. Global Metastatic Melanoma Drug Revenue Market Share by Region (2017-2022)
Table 15. Global Metastatic Melanoma Drug Revenue by Region (2023-2028) & (US$ Million)
Table 16. Global Metastatic Melanoma Drug Revenue Market Share by Region (2023-2028)
Table 17. Global Metastatic Melanoma Drug Sales by Manufacturers (2017-2022) & (K Pcs)
Table 18. Global Metastatic Melanoma Drug Sales Share by Manufacturers (2017-2022)
Table 19. Global Metastatic Melanoma Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 20. Global Metastatic Melanoma Drug Revenue Share by Manufacturers (2017-2022)
Table 21. Metastatic Melanoma Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 22. Global Metastatic Melanoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Metastatic Melanoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Drug as of 2021)
Table 24. Metastatic Melanoma Drug Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Metastatic Melanoma Drug Product Offered
Table 26. Date of Manufacturers Enter into Metastatic Melanoma Drug Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 29. Global Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 30. Global Metastatic Melanoma Drug Sales Share by Type (2017-2022)
Table 31. Global Metastatic Melanoma Drug Sales Share by Type (2023-2028)
Table 32. Global Metastatic Melanoma Drug Revenue by Type (2017-2022) & (US$ Million)
Table 33. Global Metastatic Melanoma Drug Revenue by Type (2023-2028) & (US$ Million)
Table 34. Global Metastatic Melanoma Drug Revenue Share by Type (2017-2022)
Table 35. Global Metastatic Melanoma Drug Revenue Share by Type (2023-2028)
Table 36. Metastatic Melanoma Drug Price by Type (2017-2022) & (USD/Pcs)
Table 37. Global Metastatic Melanoma Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 38. Global Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 39. Global Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 40. Global Metastatic Melanoma Drug Sales Share by Application (2017-2022)
Table 41. Global Metastatic Melanoma Drug Sales Share by Application (2023-2028)
Table 42. Global Metastatic Melanoma Drug Revenue by Application (2017-2022) & (US$ Million)
Table 43. Global Metastatic Melanoma Drug Revenue by Application (2023-2028) & (US$ Million)
Table 44. Global Metastatic Melanoma Drug Revenue Share by Application (2017-2022)
Table 45. Global Metastatic Melanoma Drug Revenue Share by Application (2023-2028)
Table 46. Metastatic Melanoma Drug Price by Application (2017-2022) & (USD/Pcs)
Table 47. Global Metastatic Melanoma Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 48. North America Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 49. North America Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 50. North America Metastatic Melanoma Drug Revenue by Type (2017-2022) & (US$ Million)
Table 51. North America Metastatic Melanoma Drug Revenue by Type (2023-2028) & (US$ Million)
Table 52. North America Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 53. North America Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 54. North America Metastatic Melanoma Drug Revenue by Application (2017-2022) & (US$ Million)
Table 55. North America Metastatic Melanoma Drug Revenue by Application (2023-2028) & (US$ Million)
Table 56. North America Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 57. North America Metastatic Melanoma Drug Sales by Country (2023-2028) & (K Pcs)
Table 58. North America Metastatic Melanoma Drug Revenue by Country (2017-2022) & (US$ Million)
Table 59. North America Metastatic Melanoma Drug Revenue by Country (2023-2028) & (US$ Million)
Table 60. Europe Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 61. Europe Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 62. Europe Metastatic Melanoma Drug Revenue by Type (2017-2022) & (US$ Million)
Table 63. Europe Metastatic Melanoma Drug Revenue by Type (2023-2028) & (US$ Million)
Table 64. Europe Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 65. Europe Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 66. Europe Metastatic Melanoma Drug Revenue by Application (2017-2022) & (US$ Million)
Table 67. Europe Metastatic Melanoma Drug Revenue by Application (2023-2028) & (US$ Million)
Table 68. Europe Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 69. Europe Metastatic Melanoma Drug Sales by Country (2023-2028) & (K Pcs)
Table 70. Europe Metastatic Melanoma Drug Revenue by Country (2017-2022) & (US$ Million)
Table 71. Europe Metastatic Melanoma Drug Revenue by Country (2023-2028) & (US$ Million)
Table 72. Asia Pacific Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 73. Asia Pacific Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 74. Asia Pacific Metastatic Melanoma Drug Revenue by Type (2017-2022) & (US$ Million)
Table 75. Asia Pacific Metastatic Melanoma Drug Revenue by Type (2023-2028) & (US$ Million)
Table 76. Asia Pacific Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 77. Asia Pacific Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 78. Asia Pacific Metastatic Melanoma Drug Revenue by Application (2017-2022) & (US$ Million)
Table 79. Asia Pacific Metastatic Melanoma Drug Revenue by Application (2023-2028) & (US$ Million)
Table 80. Asia Pacific Metastatic Melanoma Drug Sales by Region (2017-2022) & (K Pcs)
Table 81. Asia Pacific Metastatic Melanoma Drug Sales by Region (2023-2028) & (K Pcs)
Table 82. Asia Pacific Metastatic Melanoma Drug Revenue by Region (2017-2022) & (US$ Million)
Table 83. Asia Pacific Metastatic Melanoma Drug Revenue by Region (2023-2028) & (US$ Million)
Table 84. Latin America Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 85. Latin America Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 86. Latin America Metastatic Melanoma Drug Revenue by Type (2017-2022) & (US$ Million)
Table 87. Latin America Metastatic Melanoma Drug Revenue by Type (2023-2028) & (US$ Million)
Table 88. Latin America Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 89. Latin America Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 90. Latin America Metastatic Melanoma Drug Revenue by Application (2017-2022) & (US$ Million)
Table 91. Latin America Metastatic Melanoma Drug Revenue by Application (2023-2028) & (US$ Million)
Table 92. Latin America Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 93. Latin America Metastatic Melanoma Drug Sales by Country (2023-2028) & (K Pcs)
Table 94. Latin America Metastatic Melanoma Drug Revenue by Country (2017-2022) & (US$ Million)
Table 95. Latin America Metastatic Melanoma Drug Revenue by Country (2023-2028) & (US$ Million)
Table 96. Middle East and Africa Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 97. Middle East and Africa Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 98. Middle East and Africa Metastatic Melanoma Drug Revenue by Type (2017-2022) & (US$ Million)
Table 99. Middle East and Africa Metastatic Melanoma Drug Revenue by Type (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 101. Middle East and Africa Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 102. Middle East and Africa Metastatic Melanoma Drug Revenue by Application (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Metastatic Melanoma Drug Revenue by Application (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 105. Middle East and Africa Metastatic Melanoma Drug Sales by Country (2023-2028) & (K Pcs)
Table 106. Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2023-2028) & (US$ Million)
Table 108. Merck & Co., Inc. Corporation Information
Table 109. Merck & Co., Inc. Description and Major Businesses
Table 110. Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 111. Merck & Co., Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Merck & Co., Inc. Recent Developments
Table 113. Merck KGaA Corporation Information
Table 114. Merck KGaA Description and Major Businesses
Table 115. Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 116. Merck KGaA Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Merck KGaA Recent Developments
Table 118. Millennium Pharmaceuticals, Inc. Corporation Information
Table 119. Millennium Pharmaceuticals, Inc. Description and Major Businesses
Table 120. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 121. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Millennium Pharmaceuticals, Inc. Recent Developments
Table 123. Morphotek, Inc. Corporation Information
Table 124. Morphotek, Inc. Description and Major Businesses
Table 125. Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 126. Morphotek, Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Morphotek, Inc. Recent Developments
Table 128. NewLink Genetics Corporation Corporation Information
Table 129. NewLink Genetics Corporation Description and Major Businesses
Table 130. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 131. NewLink Genetics Corporation Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. NewLink Genetics Corporation Recent Developments
Table 133. Novartis AG Corporation Information
Table 134. Novartis AG Description and Major Businesses
Table 135. Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 136. Novartis AG Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Novartis AG Recent Developments
Table 138. Omeros Corporation Corporation Information
Table 139. Omeros Corporation Description and Major Businesses
Table 140. Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 141. Omeros Corporation Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Omeros Corporation Recent Developments
Table 143. Oncolytics Biotech Inc. Corporation Information
Table 144. Oncolytics Biotech Inc. Description and Major Businesses
Table 145. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 146. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Oncolytics Biotech Inc. Recent Developments
Table 148. OncoSec Medical Inc. Corporation Information
Table 149. OncoSec Medical Inc. Description and Major Businesses
Table 150. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 151. OncoSec Medical Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. OncoSec Medical Inc. Recent Developments
Table 153. Ono Pharmaceutical Co., Ltd. Corporation Information
Table 154. Ono Pharmaceutical Co., Ltd. Description and Major Businesses
Table 155. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 156. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Ono Pharmaceutical Co., Ltd. Recent Developments
Table 158. Pfizer Inc. Corporation Information
Table 159. Pfizer Inc. Description and Major Businesses
Table 160. Pfizer Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 161. Pfizer Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. Pfizer Inc. Recent Developments
Table 163. Pharmis Biofarmaceutica, Lda. Corporation Information
Table 164. Pharmis Biofarmaceutica, Lda. Description and Major Businesses
Table 165. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 166. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Pharmis Biofarmaceutica, Lda. Recent Developments
Table 168. Philogen S.p.A. Corporation Information
Table 169. Philogen S.p.A. Description and Major Businesses
Table 170. Philogen S.p.A. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 171. Philogen S.p.A. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Philogen S.p.A. Recent Developments
Table 173. Plexxikon Inc. Corporation Information
Table 174. Plexxikon Inc. Description and Major Businesses
Table 175. Plexxikon Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 176. Plexxikon Inc. Metastatic Melanoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 177. Plexxikon Inc. Recent Developments
Table 178. Key Raw Materials Lists
Table 179. Raw Materials Key Suppliers Lists
Table 180. Metastatic Melanoma Drug Distributors List
Table 181. Metastatic Melanoma Drug Customers List
Table 182. Metastatic Melanoma Drug Market Trends
Table 183. Metastatic Melanoma Drug Market Drivers
Table 184. Metastatic Melanoma Drug Market Challenges
Table 185. Metastatic Melanoma Drug Market Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Metastatic Melanoma Drug Product Picture
Figure 3. Global Metastatic Melanoma Drug Market Share by Type in 2021 & 2028
Figure 3. AGI-134 Product Picture
Figure 4. ALT-801 Product Picture
Figure 5. ALT-803 Product Picture
Figure 6. AMG-232 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Metastatic Melanoma Drug Market Share by Application in 2021 & 2028
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Metastatic Melanoma Drug Report Years Considered
Figure 13. Global Metastatic Melanoma Drug Sales 2017-2028 (K Pcs)
Figure 14. Global Metastatic Melanoma Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Metastatic Melanoma Drug Revenue 2017-2028 (US$ Million)
Figure 16. Global Metastatic Melanoma Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 17. Global Metastatic Melanoma Drug Sales Market Share by Region (2017-2022)
Figure 18. Global Metastatic Melanoma Drug Sales Market Share by Region (2023-2028)
Figure 19. North America Metastatic Melanoma Drug Sales YoY (2017-2028) & (K Pcs)
Figure 20. North America Metastatic Melanoma Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Europe Metastatic Melanoma Drug Sales YoY (2017-2028) & (K Pcs)
Figure 22. Europe Metastatic Melanoma Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Asia-Pacific Metastatic Melanoma Drug Sales YoY (2017-2028) & (K Pcs)
Figure 24. Asia-Pacific Metastatic Melanoma Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Latin America Metastatic Melanoma Drug Sales YoY (2017-2028) & (K Pcs)
Figure 26. Latin America Metastatic Melanoma Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Middle East & Africa Metastatic Melanoma Drug Sales YoY (2017-2028) & (K Pcs)
Figure 28. Middle East & Africa Metastatic Melanoma Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 29. The Metastatic Melanoma Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 30. The Top 5 and 10 Largest Manufacturers of Metastatic Melanoma Drug in the World: Market Share by Metastatic Melanoma Drug Revenue in 2021
Figure 31. Global Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 32. Global Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 33. Global Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
Figure 34. Global Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 35. Global Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
Figure 36. North America Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 37. North America Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
Figure 38. North America Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 39. North America Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
Figure 40. North America Metastatic Melanoma Drug Sales Share by Country (2017-2028)
Figure 41. North America Metastatic Melanoma Drug Revenue Share by Country (2017-2028)
Figure 42. U.S. Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 43. Canada Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 44. Europe Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 45. Europe Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
Figure 46. Europe Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 47. Europe Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
Figure 48. Europe Metastatic Melanoma Drug Sales Share by Country (2017-2028)
Figure 49. Europe Metastatic Melanoma Drug Revenue Share by Country (2017-2028)
Figure 50. Germany Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 51. France Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 52. U.K. Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 53. Italy Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Russia Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 55. Asia Pacific Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 56. Asia Pacific Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
Figure 57. Asia Pacific Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 58. Asia Pacific Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
Figure 59. Asia Pacific Metastatic Melanoma Drug Sales Share by Region (2017-2028)
Figure 60. Asia Pacific Metastatic Melanoma Drug Revenue Share by Region (2017-2028)
Figure 61. China Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 62. Japan Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 63. South Korea Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 64. India Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 65. Australia Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Taiwan Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Indonesia Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Thailand Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Malaysia Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Philippines Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 71. Latin America Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 72. Latin America Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
Figure 73. Latin America Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 74. Latin America Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
Figure 75. Latin America Metastatic Melanoma Drug Sales Share by Country (2017-2028)
Figure 76. Latin America Metastatic Melanoma Drug Revenue Share by Country (2017-2028)
Figure 77. Mexico Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 78. Brazil Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 79. Argentina Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 80. Middle East and Africa Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Metastatic Melanoma Drug Sales Share by Country (2017-2028)
Figure 85. Middle East and Africa Metastatic Melanoma Drug Revenue Share by Country (2017-2028)
Figure 86. Turkey Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 87. Saudi Arabia Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 88. U.A.E Metastatic Melanoma Drug Revenue (2017-2028) & (US$ Million)
Figure 89. Metastatic Melanoma Drug Value Chain
Figure 90. Metastatic Melanoma Drug Production Process
Figure 91. Channels of Distribution
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed

Global Pancreatic Endocrine Tumor Drug Market Insights and Forecast to 2028
QY2203B14340 2022年3月 90Pages
新型コロナウイルス感染症のパンデミックにより、世界の膵臓内分泌腫瘍（PNET）治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に膵臓...

フィブリノゲン欠乏症治療薬のグローバル市場インサイト・予測（～2028年）

Global Fibrinogen Deficiency Drug Market Insights and Forecast to 2028
QY2203B05315 2022年3月 99Pages
新型コロナウイルス感染症のパンデミックにより、世界のフィブリノゲン欠乏症治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にフィブリノ...

植物薬のグローバル市場インサイト・予測（～2028年）

Global Botanical Drug Market Insights and Forecast to 2028
QY2203B11006 2022年3月 119Pages
新型コロナウイルス感染症のパンデミックにより、世界の植物薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に植物薬の世界市場のxxx％を占...

注射用薬物送達システムのグローバル市場インサイト・予測（～2028年）

Global Injectable Drug Delivery Systems Market Insights, Forecast to 2028
QY2203B12156 2022年3月 109Pages
新型コロナウイルス感染症のパンデミックにより、世界の注射用薬物送達システムの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に注射用薬物送達...

徐放性薬物送達システムのグローバル市場インサイト・予測（～2028年）

Global Sustained Release Drug Delivery Systems Market Insights, Forecast to 2028
QY2203B10774 2022年3月 129Pages
新型コロナウイルス感染症のパンデミックにより、世界の徐放性薬物送達システムの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に徐放性薬物送達...

1,5-ジフェニルカルバゾンのグローバル市場インサイト・予測（～2028年）

Global 1,5-Diphenyl Carbazone Market Insights, Forecast to 2028
QY2203B00036 2022年3月 91Pages
新型コロナウイルス感染症のパンデミックにより、世界の1,5-ジフェニルカルバゾンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に1,5-...

カスパーゼ8のグローバル市場インサイト・予測（～2028年）

Global Caspase 8 Market Insights and Forecast to 2028
QY2203B02252 2022年3月 73Pages
新型コロナウイルス感染症のパンデミックにより、世界のカスパーゼ8の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にカスパーゼ8の世界市場の...

球状セルロースアセテートのグローバル市場インサイト・予測（～2028年）

Global Spherical Cellulose Acetate Market Insights, Forecast to 2028
QY2203B08436 2022年3月 93Pages
新型コロナウイルス感染症のパンデミックにより、世界の球状セルロースアセテートの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に球状セルロー...

ヨウ素-125のグローバル市場インサイト・予測（～2028年）

Global Iodine-125 Market Insights and Forecast to 2028
QY2203B06788 2022年3月 74Pages
新型コロナウイルス感染症のパンデミックにより、世界のヨウ素-125の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にヨウ素-125の世界市...

犬用関節炎治療薬のグローバル市場インサイト・予測（～2028年）

Global Arthritis Treatment Medicine for Dogs Market Insights, Forecast to 2028
QY2203B08941 2022年3月 90Pages
新型コロナウイルス感染症のパンデミックにより、世界の犬用関節炎治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に犬用関節炎治療薬の世...

膵臓内分泌腫瘍（PNET）治療薬のグローバル市場インサイト・予測（～2028年） Market Analysis and Insights: Global Pancreatic Endocrine Tumor Drug Market Due to the COVID-19 pandemic, the global Pancreatic Endocrine Tumor Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review…
フィブリノゲン欠乏症治療薬のグローバル市場インサイト・予測（～2028年） Market Analysis and Insights: Global Fibrinogen Deficiency Drug Market Due to the COVID-19 pandemic, the global Fibrinogen Deficiency Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. F…
植物薬のグローバル市場インサイト・予測（～2028年） Sales outsourcing is simply this: outsourcing a portion or entire sales activities to a trusted 3rd party sales team. Using a sales outsourcing partner allows companies to attract and maintain a sales force without having to make them full or part-time employees. Market Analysis and Insights: Global…
注射用薬物送達システムのグローバル市場インサイト・予測（～2028年） Injectable drug delivery is defined as introduction of a drug or drugs in the patient by using a delivery device. Injectables allow the transport of drugs formulated in liquid form, directly in the body. Even though, they may be designed to transport the drug to specific part of the body. Market Ana…
徐放性薬物送達システムのグローバル市場インサイト・予測（～2028年） Sustained Release Drug Delivery System (SRDDS) is designed to release a drug at a predetermined rate by maintaining a constant drug level for a specific period of time with minimum side effects. Market Analysis and Insights: Global Sustained Release Drug Delivery Systems Market Due to the COVID-19 p…